MannKind Corporation (MNKD)
NASDAQ: MNKD · Real-Time Price · USD
3.490
-0.010 (-0.29%)
At close: Sep 22, 2026, 4:00 PM EDT
3.362
-0.129 (-3.68%)
After-hours: Sep 22, 2026, 7:30 PM EDT
MannKind Employees
As of December 31, 2025, MannKind had 592 total employees, including 591 full-time and 1 part-time employees. The number of employees increased by 185 or 45.45% compared to the previous year.
Employees
592
Change (1Y)
185
Growth (1Y)
45.45%
Revenue / Employee
$664,914
Profits / Employee
-$73,672
Market Cap
1.12B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 592 | 185 | 45.45% | 591 | 1 |
| Dec 31, 2024 | 407 | -7 | -1.69% | 403 | 4 |
| Dec 31, 2023 | 414 | 19 | 4.81% | 411 | 3 |
| Dec 31, 2022 | 395 | 46 | 13.18% | 391 | 4 |
| Dec 31, 2021 | 349 | 108 | 44.81% | 348 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 704 |
| Replimune Group | 465 |
| MoonLake Immunotherapeutics | 130 |
| Odyssey Therapeutics | 100 |
| Apnimed | 81 |
| Alto Neuroscience | 68 |
| Seaport Therapeutics | 58 |
| Jade Biosciences | 55 |
MNKD News
- 7 days ago - MannKind Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 11 days ago - MannKind management to meet with Cantor - TheFly
- 13 days ago - MannKind and Rose Pharma sign licensing and collaboration agreement - TheFly
- 13 days ago - MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management - GlobeNewsWire
- 20 days ago - MannKind to Present at Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - MannKind price target lowered to $13 from $14 at Wells Fargo - TheFly
- 6 weeks ago - MannKind reports Q2 EPS (6c), consensus 2c - TheFly
- 6 weeks ago - MannKind Earnings Call Transcript: Q2 2026 - Transcripts